Inequitable Long-Term Outcomes for an Indigenous Population After Definitive Treatment of Patients With Graves Disease.

BACKGROUND

Māori, the indigenous people of Aotearoa/New Zealand, have an increased incidence of Graves disease and often require more than one radioiodine (RAI) dose, raising the question as to whether surgery may be preferable in this population. However, there is a lack of outcome data after definitive therapy in an indigenous population.

AIM

To assess ethnic differences in thyroid status after definitive therapy for Graves disease.

METHODS

Single-center retrospective review of patients treated by RAI or thyroidectomy from 1 December 2001 to 31 March 2013. TSH levels at 1, 2, 5, and 10 years after treatment were recorded.

RESULTS

A total of 798 patients were included: 589 received RAI, and 209 underwent surgery. Overall, 48% of patients were euthyroid at 1 year after definitive treatment, and 63.5% were euthyroid by 10 years. Māori were less likely to be euthyroid when compared with Europeans at all time points (, 29.7% vs 57.3% at 1 year and 52.2% vs 70.9% at 10 years, < 0.0005). Māori were more likely to receive more than one dose of RAI compared with Europeans (30.2% vs 14.2%, < 0.0005). Persistent thyrotoxicosis at 1 year after RAI was seen in 25.8% of Māori compared with 8.3% of Europeans ( < 0.0005).

CONCLUSIONS

Māori have lower rates of optimal thyroid levels than their European counterparts at all time points studied. Early disparity was associated with a higher RAI failure rate. Late differences were due to higher rates of untreated hypothyroidism. Overall, euthyroid rates were low, indicating the need for improvement in care, particularly for indigenous peoples.